Market Cap 471.12M
Revenue (ttm) 0.00
Net Income (ttm) -15.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 83,300
Avg Vol 159,102
Day's Range N/A - N/A
Shares Out 6.68M
Stochastic %K 49%
Beta 1.46
Analysts Strong Sell
Price Target $110.50

Company Profile

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imagi...

Industry: Biotechnology
Sector: Healthcare
Phone: 847 388 0349
Address:
1000 Skokie Boulevard, Suite 350, Wilmette, United States
trading_momentum_x
trading_momentum_x Dec. 23 at 3:09 AM
$MNPR has reversed sharply off the 64–65 demand zone, forming a clear sequence of higher lows and pushing back toward equilibrium. The bounce is impulsive relative to the prior decline, suggesting active dip-buying rather than a passive drift. Price is now testing the 72–73 equilibrium / mid-range area, where short-term pauses are likely. The larger overhead 79–80 supply zone remains the key upside cap and will likely attract sellers on any continuation. Key levels: Resistance: 72–73 initially, then 79–80 Support: 68–69, followed by 65–64 if momentum fades Bottom line: MNPR is in a strong short-term recovery off demand, but it is now entering a decision area. Acceptance above the low-70s would keep the rebound intact; failure would shift the move back into corrective territory.
0 · Reply
ZacksResearch
ZacksResearch Dec. 22 at 3:18 PM
Biotech boom in 2025: Can $IONS, $GPCR, $MNPR, and $KOD keep the momentum? IONS soared 120.5% with strong pipeline progress and favorable regulatory developments. GPCR up 127.2% on promising obesity drug data. MNPR skyrocketed 185.9% fueled by positive investor expectations regarding its lead candidate. KOD surged 181.1% on solid late-stage pipeline potential. See the full breakdown here 👉 https://www.zacks.com/stock/news/2807434/what-awaits-these-4-biotech-stocks-that-more-than-doubled-in-2025?cid=sm-stocktwits-2-2807434-body-25804&ADID=SYND_STOCKTWITS_TWEET_2_2807434_BODY_25804
0 · Reply
ZacksResearch
ZacksResearch Dec. 22 at 2:18 PM
These biotech names more than doubled in 2025 — momentum or mania? $IONS, $GPCR, $MNPR, and $KOD all surged over 100% in 2025, fueled by policy clarity, a revival in M&A activity, and key clinical wins pushing biotech momentum into 2026. Which of these winners still has room to run — and which could fade? Full breakdown here 👉 https://www.zacks.com/stock/news/2807434/what-awaits-these-4-biotech-stocks-that-more-than-doubled-in-2025?cid=sm-stocktwits-2-2807434-teaser-25785&ADID=SYND_STOCKTWITS_TWEET_2_2807434_TEASER_25785
0 · Reply
RadioIsotope25
RadioIsotope25 Dec. 20 at 8:34 PM
How Radioisotopes Are Being Used to De-Risk Antibody-Drug Conjugate (ADC) Development $RADX $IMNM $MNPR $PYXS https://blog.championsoncology.com/blog/how-radiopharmaceuticals-are-being-used-to-de-risk-antibody-drug-conjugate-adc-development
0 · Reply
RadioIsotope25
RadioIsotope25 Dec. 20 at 7:31 PM
$MNPR RADX on Monday now at $5.19 do your DD
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 10 at 3:13 AM
0 · Reply
IcePhoenix
IcePhoenix Dec. 7 at 3:36 PM
0 · Reply
ssdsddssd2
ssdsddssd2 Dec. 7 at 2:30 PM
0 · Reply
RadioIsotope25
RadioIsotope25 Dec. 2 at 1:45 AM
$RADX Radiopharm Theranostics $30 target at Jones Trading $NNE $ASPI $MNPR
3 · Reply
RadioIsotope25
RadioIsotope25 Nov. 25 at 3:44 PM
Therapeutic Radiopharmaceuticals: Download 2025 Global Report - Clinical Trials Arena $RADX $CBSR $CATX $MNPR https://www.clinicaltrialsarena.com/sponsored/therapeutic-radiopharmaceuticals-download-2025-global-report/
0 · Reply
Latest News on MNPR
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

May 7, 2025, 2:30 AM EDT - 8 months ago

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025


Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule


Monopar Therapeutics Announces 1-for-5 Reverse Stock Split

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Monopar Therapeutics Announces 1-for-5 Reverse Stock Split


Monopar and NorthStar Amend & Extend Collaboration

Jun 11, 2024, 7:30 AM EDT - 1 year ago

Monopar and NorthStar Amend & Extend Collaboration


Monopar Announces CFO Succession

May 24, 2024, 8:00 AM EDT - 1 year ago

Monopar Announces CFO Succession


trading_momentum_x
trading_momentum_x Dec. 23 at 3:09 AM
$MNPR has reversed sharply off the 64–65 demand zone, forming a clear sequence of higher lows and pushing back toward equilibrium. The bounce is impulsive relative to the prior decline, suggesting active dip-buying rather than a passive drift. Price is now testing the 72–73 equilibrium / mid-range area, where short-term pauses are likely. The larger overhead 79–80 supply zone remains the key upside cap and will likely attract sellers on any continuation. Key levels: Resistance: 72–73 initially, then 79–80 Support: 68–69, followed by 65–64 if momentum fades Bottom line: MNPR is in a strong short-term recovery off demand, but it is now entering a decision area. Acceptance above the low-70s would keep the rebound intact; failure would shift the move back into corrective territory.
0 · Reply
ZacksResearch
ZacksResearch Dec. 22 at 3:18 PM
Biotech boom in 2025: Can $IONS, $GPCR, $MNPR, and $KOD keep the momentum? IONS soared 120.5% with strong pipeline progress and favorable regulatory developments. GPCR up 127.2% on promising obesity drug data. MNPR skyrocketed 185.9% fueled by positive investor expectations regarding its lead candidate. KOD surged 181.1% on solid late-stage pipeline potential. See the full breakdown here 👉 https://www.zacks.com/stock/news/2807434/what-awaits-these-4-biotech-stocks-that-more-than-doubled-in-2025?cid=sm-stocktwits-2-2807434-body-25804&ADID=SYND_STOCKTWITS_TWEET_2_2807434_BODY_25804
0 · Reply
ZacksResearch
ZacksResearch Dec. 22 at 2:18 PM
These biotech names more than doubled in 2025 — momentum or mania? $IONS, $GPCR, $MNPR, and $KOD all surged over 100% in 2025, fueled by policy clarity, a revival in M&A activity, and key clinical wins pushing biotech momentum into 2026. Which of these winners still has room to run — and which could fade? Full breakdown here 👉 https://www.zacks.com/stock/news/2807434/what-awaits-these-4-biotech-stocks-that-more-than-doubled-in-2025?cid=sm-stocktwits-2-2807434-teaser-25785&ADID=SYND_STOCKTWITS_TWEET_2_2807434_TEASER_25785
0 · Reply
RadioIsotope25
RadioIsotope25 Dec. 20 at 8:34 PM
How Radioisotopes Are Being Used to De-Risk Antibody-Drug Conjugate (ADC) Development $RADX $IMNM $MNPR $PYXS https://blog.championsoncology.com/blog/how-radiopharmaceuticals-are-being-used-to-de-risk-antibody-drug-conjugate-adc-development
0 · Reply
RadioIsotope25
RadioIsotope25 Dec. 20 at 7:31 PM
$MNPR RADX on Monday now at $5.19 do your DD
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 10 at 3:13 AM
0 · Reply
IcePhoenix
IcePhoenix Dec. 7 at 3:36 PM
0 · Reply
ssdsddssd2
ssdsddssd2 Dec. 7 at 2:30 PM
0 · Reply
RadioIsotope25
RadioIsotope25 Dec. 2 at 1:45 AM
$RADX Radiopharm Theranostics $30 target at Jones Trading $NNE $ASPI $MNPR
3 · Reply
RadioIsotope25
RadioIsotope25 Nov. 25 at 3:44 PM
Therapeutic Radiopharmaceuticals: Download 2025 Global Report - Clinical Trials Arena $RADX $CBSR $CATX $MNPR https://www.clinicaltrialsarena.com/sponsored/therapeutic-radiopharmaceuticals-download-2025-global-report/
0 · Reply
ScreenerIQ
ScreenerIQ Nov. 23 at 5:49 PM
Some Stocks showing strong relative strength. Filtered on '5-Day Return'. Please DYOResearch. Some examples: $EYPT $MNPR $NTRA $DY #StockMarket #investing #Trading
0 · Reply
Stanfordfund
Stanfordfund Nov. 22 at 1:20 PM
$MNPR Never sell!
0 · Reply
milanmoses
milanmoses Nov. 19 at 5:14 PM
Big eyes on $MNPR: their Wilson disease candidate + radiopharma combo is rare.
0 · Reply
RadioIsotope25
RadioIsotope25 Nov. 19 at 2:48 PM
0 · Reply
notreload_ai
notreload_ai Nov. 14 at 4:43 PM
$BTM $FISV $MNPR $PGR $TCRX -- MarketBeat
0 · Reply
JarvisFlow
JarvisFlow Nov. 14 at 11:54 AM
Raymond James has adjusted their stance on Monopar Therapeutics ( $MNPR ), setting the rating to Outperform with a target price of 142 → 123.
0 · Reply
JarvisFlow
JarvisFlow Nov. 13 at 9:15 PM
Chardan Capital has updated their rating for Monopar Therapeutics ( $MNPR ) to Buy with a price target of 100.
0 · Reply
RadioIsotope25
RadioIsotope25 Nov. 12 at 11:19 PM
Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204 $IMNM $RADX $MNPR https://finance.yahoo.com/news/radiopharm-theranostics-starts-enrollment-third-133000810.html
0 · Reply
stockmoe12
stockmoe12 Nov. 11 at 2:19 PM
$QNRX marketcap us so low $100 is aoso very cheap ... look at how $MNPR and $PVLA did last frw month
0 · Reply
topstockalerts
topstockalerts Nov. 10 at 3:17 PM
Monopar Therapeutics Inc. stock rose before market open Monday following the release of new data showing improvement in copper balance for Wilson's disease patients treated with choline tetrathiomolybdate. The biopharma company presented Phase 2 copper balance study ALXN1840-WD-204 results at the American Association for the Study of Liver Diseases meeting in Washington, D.C. The data showed ALXN1840 (choline tetrathiomolybdate) led to rapid and sustained improvement in daily copper balance, primarily through increased fecal copper excretion. Patients treated with ALXN1840 showed a significantly lower mean daily copper balance compared to their baseline. Improvements were seen both during the initial 15 mg daily dosing period and throughout the treatment. The findings aligned with those published in The Journal of Hepatology in September 2025, showing ALXN1840's rapid improvement of copper balance in Wilson's disease patients. $MNPR
0 · Reply
Dbi2
Dbi2 Nov. 10 at 2:06 PM
$MNPR 💥
0 · Reply
OpenOutcrier
OpenOutcrier Nov. 10 at 1:43 PM
$MNPR (+6.2% pre) Monopar Therapeutics Unveils Promising Phase 2 Study Results https://ooc.bz/l/83865
0 · Reply